You are here

Novartis

Spark/Novartis eye gene therapy nears EU market – but at what price?

Pharmaforum

Sun, 09/23/18 - 10:36 pm

Spark Therapeutics

Ex-Novartis Chief Joins uBiome to Help Launch Discovery and Development Business

CP Wire

Fri, 09/21/18 - 09:38 am

NICE rejects Novartis’ CAR-T in adult lymphoma

Pharmaforum

Wed, 09/19/18 - 11:22 pm

diffuse large B-cell lymphoma

Novartis links bonuses to ethics in bid to rebuild reputation

Reuters

Tue, 09/18/18 - 10:08 am

Pfizer, Glaxo, Novo, Novartis plants unfazed by hurricane, resume production

Fierce Pharma

Mon, 09/17/18 - 03:16 pm

drug manufacturing

UCSD researchers identify mechanism, target in NASH

BioCentury

Sat, 09/15/18 - 02:12 pm

Amgen, Sandoz begin biosimilar trial with top-selling Enbrel at stake

Biopharma Dive

Thu, 09/13/18 - 11:19 pm

Novartis, Novo, Glaxo and others hunker down as hurricane sweeps in

Fierce Pharma

Thu, 09/13/18 - 11:14 pm

The Curious Case Of Gleevec Pricing

Forbes

Wed, 09/12/18 - 11:13 am

Novartis makes it official: Alcon is moving its HQ from Texas to Geneva ahead of a spinoff

Endpoints

Tue, 09/11/18 - 09:21 am

Mylan Strikes $463 Million Deal With Novartis for CF Product Line

BioSpace

Fri, 09/7/18 - 11:03 am

cystic fibrosis

Gilead, Galapagos clear another PhII hurdle for filgotinib, but can they hope to catch up with Novartis’ Cosentyx?

Endpoints

Thu, 09/6/18 - 10:15 am

Gilead Sciences

ankylosing spondylitis

Novartis sells parts of Sandoz for $1bn

Pharmaforum

Thu, 09/6/18 - 09:40 am

Novartis CAR-T therapy snags UK coverage, cutting list price 23% from US

Biopharma Dive

Wed, 09/5/18 - 10:01 pm

Novartis to streamline production in response to lower U.S. prices: NZZ am Sonntag

Yahoo/Reuters

Sat, 09/1/18 - 03:40 pm

Novartis says glaucoma stent setback will not derail Alcon spin-off

Yahoo/Reuters

Wed, 08/29/18 - 10:34 am

CyPass Micro-Stent

Novartis announces new €78m plant and 450 new jobs to manufacture Kymriah in EU

GoinPharma

Tue, 08/28/18 - 07:58 pm

acute lymphoblastic leukemia

Novartis wins a key OK for Kymriah, but continuing manufacturing woes hobble rollout — rival Gilead CAR-T breaks into Europe

Endpoints

Mon, 08/27/18 - 10:10 am

drug manufacturing

LifeMax Acquires Rights to Orphan Drug for Netherton Syndrome from Novartis

CP Wire

Mon, 08/27/18 - 09:54 am

LifeMax Laboratories

Netherton Syndrome

LifeMax Acquires Rights to Orphan Drug for Netherton Syndrome from Novartis

Mon, 08/27/18 - 09:12 am

LifeMax Laboratories

Netherton Syndrome

Pages